TGFB2 and atherosclerosis: In brief, recent work has shown that (1) TGF-β2 may be more effective in inducing EndMT, and induction may depend on anatomical origin, (2) TGF-β2 may be predominantly secreted from VSMCs in atherosclerosis, and (3) a high level of TGF-β2 in the plaque may be associated with plaque stability and a lower risk of future CV events.